Refine Results
  1. "Colorectal Disease Management Team"
Formats
  1. Journal Article (1364)
  2. Meeting Abstract (498)
  3. Book Section (104)
  4. Conference Paper (28)
  5. Book Whole (11)
Groups
  1. Colorectal Disease Management Team (2005)
  2. Gastrointestinal Disease Management Team (1835)
  3. Hepatopancreaticobiliary Disease Management Team (1551)
  4. Solid Tumor Oncology Division (690)
  5. Gastrointestinal Oncology Service (665)
  6. Surgery (595)

More Groups

People
  1. David Klimstra (497)
  2. Yuman Fong (259)
  3. Leonard Saltz (220)
  4. Laura Tang (147)
  5. David Ilson (143)
  6. David Kelsen (141)

More People

Years
  1. 2019 (1)
  2. 2018 (76)
  3. 2017 (113)
  4. 2016 (115)
  5. 2015 (100)
  6. 2014 (95)

More Years

Publications
  1. Modern Pathology (134)
  2. Journal of Clinical Oncology (122)
  3. Laboratory Investigation (116)
  4. American Journal of Surgical Pathology (63)
  5. Annals of Oncology (44)
  6. Annals of Surgical Oncology (42)

More Publications

Publishers
  1. Nature Publishing Group (290)
  2. Elsevier Inc. (238)
  3. Lippincott Williams & Wilkins (205)
  4. Springer (153)
  5. American Society of Clinical Oncology (133)
  6. American Association for Cancer Research (88)

More Publishers

Results (2005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Proinsulin expressing neuroendocrine tumors of the pancreas: An underrecognized entity
    Journal Article

    Celli, R.; Tang, L. H.; Cai, G.; Freedman-Weiss, M.; Colunga, M.; Salem, R. R.; Majumdar, S.; Jain, D.
    Pancreas (2019)

    Fulltext@MSK | Save
  • Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC
    Meeting Abstract

    Hellmann, M. D.; Antonia, S. J.; Balmanoukian, A. S.; Brahmer, J. R.; Ou, S. H. I.; Kim, S. W.; Ahn, M. J.; Kim, D. W.; Gutierrez, M.; Liu, S. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • BEACON CRC study safety lead-in (SLI) in patients with BRAF(V600E) metastatic colorectal cancer (mCRC): Efficacy and tumor markers
    Meeting Abstract

    Van Cutsem, E.; Cuyle, P. J.; Huijberts, S.; Yaeger, R.; Schellens, J. H. M.; Elez, E.; Tabernero, J.; Fakih, M.; Montagut, C.; Peeters, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database
    Meeting Abstract

    Ou, F. S.; Lou, Y.; Van Cutsem, E.; Saltz, L.; Schmoll, H. J.; Goldberg, R. M.; Hoff, P.; Douillard, J. Y.; Hecht, J. R.; Hurwitz, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy outcomes with bevacizumab added to chemotherapy (bev + CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Loupakis, F.; Hurwitz, H. I.; Saltz, L.; Arnold, D.; Grothey, A.; Nguyen, Q. L.; Osborne, S.; Yau, L.; Talbot, J.; Srock, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma
    Meeting Abstract

    Fuchs, C. S.; Shitara, K.; Di Bartolomeo, M.; Lonardi, S.; Al-Batran, S. E.; Van Cutsem, E.; Ilson, D. H.; Tabernero, J.; Chau, I.; Ducreux, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database
    Meeting Abstract

    Ferraro, D. A.; Zalcberg, J. R.; Shi, Q.; Meyers, J. P.; Seymour, M. T.; Saltz, L.; Maughan, T.; Goldberg, R. M.; Van Cutsem, E.; Heinemann, V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer
    Meeting Abstract

    Borad, M. J.; Shroff, R. T.; Abou-Alfa, G. K.; Hecht, J. R.; Bullock, A. J.; Ritch, P. S.; Chondros, D.; Muhsin, M.; Oh, D. Y.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation
    Meeting Abstract

    Abou-Alfa, G. K.; Valle, J. W.; Kelley, R. K.; Goyal, L.; Shroff, R. T.; Javle, M. M.; Borad, M. J.; Cleary, J. M.; El-Khoueiry, A. B.; Bendell, J. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
    Journal Article

    Rindi, G.; Klimstra, D. S.; Abedi-Ardekani, B.; Asa, S. L.; Bosman, F. T.; Brambilla, E.; Busam, K. J.; de Krijger, R. R.; Dietel, M.; El-Naggar, A. K.; more...
    Modern Pathology (2018)

    Fulltext@MSK | Save